MGI Tech Partners with National Cancer Centre Singapore
Friday, September 15, 2023
MGI Tech has entered into research partnership with the National Cancer Centre Singapore (NCCS) to advance the understanding of Asian-prevalent cancers through comprehensive genomic profiling.
This partnership combines the expertise of the Cancer Discovery Hub (CDH) in multi-omics molecular diagnostics and research with MGI's cutting-edge DNBSEQ™ technology for high-throughput sequencing.
In collaboration with NCCS, MGI Tech will installed its DNBSEQ-G400 sequencer at NCCS' Cancer Discovery Hub (CDH) to conduct RNA-seq analysis. The versatile benchtop sequencer is equipped with a dual Flow Cell system, offering the flexibility to accommodate a wide range of sequencing modes and applications.
With the utilisation of DNBSEQ technology, collaborative effort will focus on extensively profiling the somatic genomic landscapes of a diverse array of Asian-prevalent cancers such as head and neck, ovary, breast, stomach, colon, liver, bile duct, cervix, lung, prostate, oesophagus, and phyllodes tumours.
Together, this partnership will elucidate the underlying mechanisms and potential pathways involved in the development of cancers prevalent in Asia and to explore improved strategies for prevention, diagnosis, and treatment.
